Want to see LSTA full AI Analyst Report?
Top Page
Lisata Therapeutics
(NASDAQ:LSTA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▼(-17.58% Downside)
Action:Reiterated
Date:09/18/26
Overall score is weighed down primarily by weak financial performance (minimal and shrinking revenue, large ongoing losses, and significant cash burn) despite zero debt. Corporate events provide some offset via substantial new financing and a strategic reset, but are tempered by recent deal failure, legal overhang, and deep workforce cuts. Technicals remain mixed-to-weak with the stock still below key longer-term moving averages.
Positive Factors
Substantial funding runway
The approximately $225 million financing materially extends the company’s operating runway and supports advancement of MAR001/005 and MAR002 through Phase 2 milestones. This reduces near-term funding pressure and gives management time to pursue clinical development and potential Phase 3 preparation.
Negative Factors
Minimal and declining revenue
The company has not established meaningful commercial revenue, and the sharp decline reinforces its dependence on clinical progress and external funding rather than product sales. Large losses relative to revenue indicate that operating scale and a self-sustaining commercial model remain unproven.
Read all positive and negative factors
Positive Factors
Negative Factors
Substantial funding runway
The approximately $225 million financing materially extends the company’s operating runway and supports advancement of MAR001/005 and MAR002 through Phase 2 milestones. This reduces near-term funding pressure and gives management time to pursue clinical development and potential Phase 3 preparation.
Read all positive factors
Lisata Therapeutics (LSTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.98M
Dividend Yield0.03%
Average Volume (3M)508.20K
Price to Earnings (P/E)―
Beta (1Y)0.11
Revenue Growth-90.65%
EPS Growth26.48%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.64
Shares Outstanding9,010,937
10 Day Avg. Volume403,904
30 Day Avg. Volume508,200
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.09
Price to Sales (P/S)95.05
P/FCF Ratio-1.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.09
Revenue Forecast (FY)N/A
Lisata Therapeutics Business Overview & Revenue Model
Company Description
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily ti...
How the Company Makes Money
Lisata Therapeutics does not have publicly disclosed recurring product revenue from commercialized drugs; as a clinical-stage biotech, its ability to generate revenue is primarily tied to external funding rather than ongoing sales. The company typ...
Lisata Therapeutics Earnings Call Summary
Earnings Call Date:Nov 06, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Neutral
Lisata Therapeutics has made significant progress in its clinical programs and strategic partnerships, reflecting strong operational management and promising trial results. However, the need for additional capital for Phase III trials poses a significant challenge. The market's lack of response to positive developments highlights ongoing investor skepticism or broader market conditions.Positive Updates
Strategic Alliance with GATC Health
Lisata entered into a strategic alliance with GATC Health to use their advanced AI technology for drug discovery, identifying several development candidates for clinical development in 2026.
Negative Updates
Need for Additional Capital
The company acknowledged the need to raise substantial funds or secure partnerships to support a Phase III trial, highlighting the significant financial challenge ahead.
Read all updates
Q3-2025 Updates
Positive
Negative
Strategic Alliance with GATC Health
Lisata entered into a strategic alliance with GATC Health to use their advanced AI technology for drug discovery, identifying several development candidates for clinical development in 2026.
Read all positive updates
Company Guidance
During the Lisata Therapeutics Third Quarter 2025 Financial Results and Business Update Conference Call, the company provided guidance on several key metrics. They reported a decrease in operating expenses to $4.4 million for the third quarter of 2025, down from $5.3 million in the same period the previous year, marking a 17.3% reduction. Research and development expenses also declined by 22.9% to $2 million. The company reported a net loss of $4.2 million, compared to $4.9 million in the third quarter of 2024. Lisata highlighted their cash and cash equivalents totaling approximately $19 million as of September 30, 2025, with projections to support operations into the first quarter of 2027. Additionally, they discussed their strategic alliance with GATC Health and a nonexclusive global license agreement with Catalent, indicating a promising period ahead with several anticipated milestones.Lisata Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 100.00K | 170.00K | 1.00M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 95.00K | 24.00K | 1.00M | 0.00 | 0.00 | 0.00 |
| EBITDA | -16.01M | -17.40M | -20.61M | -22.98M | -56.63M | -28.92M |
| Net Income | -14.62M | -16.59M | -19.98M | -20.84M | -54.23M | -27.47M |
Balance Sheet | ||||||
| Total Assets | 11.03M | 17.74M | 35.00M | 54.69M | 73.03M | 97.01M |
| Cash, Cash Equivalents and Short-Term Investments | 10.44M | 15.96M | 31.25M | 50.53M | 69.23M | 94.97M |
| Total Debt | 0.00 | 0.00 | 137.00K | 168.00K | 485.00K | 714.00K |
| Total Liabilities | 3.04M | 3.14M | 5.68M | 6.80M | 6.71M | 5.01M |
| Stockholders Equity | 8.24M | 14.86M | 29.57M | 48.15M | 66.58M | 92.25M |
Cash Flow | ||||||
| Free Cash Flow | -12.32M | -15.98M | -19.36M | -20.03M | -21.45M | -22.30M |
| Operating Cash Flow | -12.32M | -15.95M | -19.36M | -20.03M | -21.17M | -22.25M |
| Investing Cash Flow | 5.15M | 15.09M | 13.23M | 10.10M | 28.91M | -54.90M |
| Financing Cash Flow | 768.00K | 599.00K | -206.00K | 385.00K | -224.00K | 85.28M |
Lisata Therapeutics Technical Analysis
Negative
1.82
Price Trends
1.45
Negative
2.40
Negative
3.09
Negative
Market Momentum
-0.05
Positive
43.64
Neutral
8.59
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSTA, the sentiment is Negative. The current price of 1.82 is above the 20-day moving average (MA) of 1.59, above the 50-day MA of 1.45, and below the 200-day MA of 3.09, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 43.64 is Neutral, neither overbought nor oversold. The STOCH value of 8.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LSTA.
Lisata Therapeutics Risk Analysis
Lisata Therapeutics disclosed 83 risk factors in its most recent earnings report. Lisata Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lisata Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $4.58M | -0.29 | -394.24% | ― | ― | 90.37% | |
48 Neutral | $72.73M | -3.13 | 288.40% | ― | ― | 86.10% | |
46 Neutral | $14.58M | -0.26 | -67.15% | ― | ― | 57.48% | |
45 Neutral | $12.98M | -0.95 | -113.79% | 0.03% | -90.65% | 26.48% | |
40 Underperform | $3.29M | >-0.01 | -201.49% | ― | ― | 99.41% |
* Healthcare Sector Average
LSTA
Lisata Therapeutics
1.49
-1.06
-41.57%
APVO
Aptevo Therapeutics
1.76
-24.34
-93.26%
CTXR
Citius Pharmaceuticals
0.54
-0.79
-59.40%
PCSA
Processa Pharmaceuticals
1.62
-3.45
-68.05%
APLM
Apollomics
23.27
4.84
26.24%
Lisata Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Lisata Therapeutics Acquires Marea, Refocuses on Cardioendocrine Portfolio
Positive
Sep 17, 2026
On September 17, 2026, Lisata Therapeutics completed a stock‑for‑stock acquisition of Marea Therapeutics, making Marea’s cardioendocrine portfolio the strategic focus of the combined company. The deal significantly reshapes Lisat...
Business Operations and StrategyExecutive/Board ChangesLegal Proceedings
Lisata Therapeutics Announces Major Workforce Reduction and Retrenchment
Negative
Aug 4, 2026
On August 3, 2026, Lisata Therapeutics’ board approved an immediate workforce reduction of approximately 72%, a drastic cost-cutting move intended to lower operating expenses and support a search for strategic options. The company expects ab...
Business Operations and StrategyLegal ProceedingsM&A Transactions
Lisata Therapeutics Ends Kuva Merger, Starts Strategic Review
Negative
Jul 24, 2026
On July 24, 2026, Lisata Therapeutics terminated its March 6, 2026 merger agreement with Kuva Labs and Kuva Acquisition Corp. after the buyer failed to accept and pay for tendered shares when the offer expired on July 20, 2026. Kuva Labs informed ...
Business Operations and StrategyM&A Transactions
Lisata Therapeutics Extends Merger Timeline with Kuva Labs
Neutral
Jul 17, 2026
On July 16, 2026, Lisata Therapeutics, Inc. and Kuva Labs Inc., along with Kuva Acquisition Corp., amended their previously announced March 6, 2026 Agreement and Plan of Merger. The amendment extends the transaction’s contractual Outside Dat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.